Can MED's Trilivy Launch and Cost Cuts Drive a Q4 Profit Turnaround? Zacks Equity Research Aug 7, 2026 Medifast's Trilivy launch and cost cuts could support a Q4 profit turnaround, but shrinking revenue and its coach base keep risks high.
MED Rallies 13.6% in the Past Month: Can the Momentum Keep Building? Zacks Equity Research Aug 7, 2026 Medifast stock gains 13.6% in a month as improving coach productivity and earnings expectations support momentum despite weaker revenue.
Is MED Worth Buying as Low Valuation Meets a High-Risk Turnaround? Zacks Equity Research Aug 7, 2026 Medifast's low valuation and improving coach productivity offer potential, but a shrinking coach base and weak growth keep the turnaround high risk.
Lamb Weston's Q4 Earnings Beat Estimates, Volume Rises 7% Y/Y Zacks Equity Research Jul 24, 2026 LW beats fiscal fourth-quarter earnings and sales estimates as higher volume drives sales growth, while earnings decline year over year.
Boston Beer Q2 Earnings Miss Estimates on Higher Marketing Costs Zacks Equity Research Jul 24, 2026 SAM's Q2 earnings and revenues fall short of estimates as weaker volumes and a 16.4% rise in marketing costs pressure results.
How Is Post Holdings Rebuilding Its Pet Food Portfolio for Growth? Zacks Equity Research Jul 22, 2026 POST is repositioning its pet food brands with pricing changes and the Nutrish relaunch to improve volumes and category performance.
Philip Morris Q2 Earnings Beat Estimates, Organic Sales Rise 7.6% Y/Y Zacks Equity Research Jul 22, 2026 PM beats second-quarter estimates as adjusted EPS rose 15.2% and organic sales climbed 7.6%, while smoke-free growth supported results.
Will e.l.f. Beauty's Skin Care Portfolio Lead the Next Leg Up? Zacks Equity Research Jul 22, 2026 e.l.f. Beauty's skin care mix rises to 23% of global consumption as e.l.f. SKIN, Naturium and rhode gain scale and pursue more share.
